Direct-Acting Oral Anticoagulants: A Resident-Based Workshop to Improve Knowledge and Confidence
Introduction Direct-acting oral anticoagulant (DOAC) prescriptions have increased steadily since the first, dabigatran, was Food and Drug Administration-approved in 2010. They have multiple advantages over vitamin K antagonists including fixed dosing without coagulation lab monitoring, rapid onset a...
Guardado en:
Autores principales: | Irsk Anderson, Vineet M. Arora |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Association of American Medical Colleges
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/511b1d672fe740d8ae9695db81278f28 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Gilda Denise Zielinski, et al.
Publicado: (2020) -
Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Clara Bonanad, et al.
Publicado: (2021) -
A summary overview of the new, direct, target-specific oral anticoagulants
por: G. L. Muntingh
Publicado: (2016) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Victoria Speed, et al.
Publicado: (2021) -
Direct oral anticoagulants; a review for the non-specialist
por: Thilina Gunawardena
Publicado: (2021)